Get started
Author

Brian Elliot

Observed institution: Genmab (United States)
OpenAlex ID: A5111453049
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2022 · Tycel Phillips, Catherine Thieblemont, et al. · Blood · 9
Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
2021 · David Belada, Jacob Haaber Christensen, et al. · Blood · 9
Abstract 1574: Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas
2021 · Christopher W. Chiu, Ida H. Hiemstra, et al. · Cancer Research · 7
Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
2022 · Lorenzo Falchi, Franck Morschhauser, et al. · Blood · 4
Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
2021 · Kim M Linton, Björn Wahlin, et al. · Blood · 4
Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)
2022 · Laurie H. Sehn, Johannes Duell, et al. · Blood · 3
Abstract 3248: Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma
2023 · Jimin Zhang, Han Si, et al. · Cancer Research · 2
POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
2026 · Lorenzo Falchi, Marcel Nijland, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
2026 · Lorenzo Falchi, Marcel Nijland, et al. · Clinical Lymphoma Myeloma & Leukemia
Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2024 · John N. Allan, Christopher P Fox, et al. · Blood
PDF
Abstract 15538: Impact of Transitioning to High Sensitivity Troponin on the Evaluation of Chest Pain in Women
2019 · Sean Dikdan, Timothy Colangelo, et al. · Circulation
Works count: 11
Citation count: 38
H-index: 4
I10-index:
Year
Topic
Type